Assignee
PURDUE PHARMACEUTICAL PRODUCTS L P
US·19 granted patents·7 pending applications·208 citations·filing 2007–2025
Top patents by PatentIndex Score
26 records- 0197US12048688B2Pharmaceutical combinations for treating cancerPURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2022·Granted Jul 30, 2024·4 cites·9 claims
- 0297US11559516B2Pharmaceutical combinations for treating cancerPURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2021·Granted Jan 24, 2023·9 cites·9 claims
- 0397US11541038B2Combination comprising a glucocorticoid and EDO-S101PURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2020·Granted Jan 3, 2023·10 cites·9 claims
- 0496US12064417B2Combination comprising a glucocorticoid and EDO-S101PURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2022·Granted Aug 20, 2024·5 cites·17 claims
- 0596US10406138B2Pharmaceutical combinations for treating cancerPURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2018·Granted Sep 10, 2019·20 cites·20 claims
- 0695US11766424B2Hodgkin lymphoma therapyPURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2022·Granted Sep 26, 2023·6 cites·18 claims
- 0795US9993482B2Pharmaceutical combination comprising a class III receptor tyrosine kinase inhibitor and the alkylating histone-deacetylase inhibitor fusion molecule EDO-S101 together with its use in the treatment of cancerPURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2015·Granted Jun 12, 2018·23 cites·22 claims
- 0894US11266631B2Hodgkin lymphoma therapyPURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2016·Granted Mar 8, 2022·15 cites·18 claims
- 0993US9096627B2Hydroxamic acid derivativesPURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2013·Granted Aug 4, 2015·27 cites·7 claims
- 1092USRE46144EHydroxamic acid derivativesPURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2010·Granted Sep 13, 2016·24 cites·18 claims
- 1191US11419853B2Compounds for treating brain cancerPURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2015·Granted Aug 23, 2022·14 cites·20 claims
- 1291US10118901B2Therapeutic agentsPURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2013·Granted Nov 6, 2018·25 cites·17 claims
- 1391US8962855B2Nitrogen mustard derivativesPURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2012·Granted Feb 24, 2015·25 cites·13 claims
- 1490US12403130B2Pharmaceutical combinations for treating cancerPURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2024·Granted Sep 2, 2025·0 cites·9 claims
- 1585US2026034102A1Hodgkin lymphoma therapyPURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2025·Application pending·0 cites
- 1684US12440475B2Hodgkin lymphoma therapyPURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2023·Granted Oct 14, 2025·0 cites·18 claims
- 1784US2025049762A1Combination comprising a glucocorticoid and edo-s101PURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2024·Application pending·0 cites
- 1881US12370177B2Compounds for treating brain cancerPURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2022·Granted Jul 29, 2025·0 cites·7 claims
- 1969US2019343807A1Pharmaceutical combinations for treating cancerPURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2019·Application pending·0 cites
- 2068USRE47491ELight transmission system for photoreactive therapyPURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2016·Granted Jul 9, 2019·1 cites·62 claims
- 2165US2024366569A1Combinations for treating cancerPURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2024·Application pending·0 cites
- 2257US2017151218A1Pharmaceutical combinations for treating cancerPURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2015·Application pending·0 cites
- 2350USRE46504ELight delivery systemPURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2007·Granted Aug 8, 2017·0 cites·45 claims
- 2446US2016213945A1Method and apparatus for treating benign prostatic hyperplasia with light-activated drug therapyPURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2016·Application pending·0 cites
- 2541US2018098969A1Hodgkin lymphoma therapyPURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2016·Application pending·0 cites
- 2636US10507205B2Methods of treating opiate dependency and preventing non-oral opiate abuse among opiate addictsPURDUE PHARMACEUTICAL PRODUCTS L P·Filed 2016·Granted Dec 17, 2019·0 cites·6 claims
Join the waitlist — get patent alerts
Get an alert when PURDUE PHARMACEUTICAL PRODUCTS L P files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →